Press Release - Oslo, Norway, February 17, 2025: Photocure ASA (OSE: PHO), The
Bladder Cancer Company, announces the presentation on February 14 of a new
abstract with study results from its U.S. bladder cancer patient registry at the
2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO
-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy
in identifying tumors undetected by WLC leading to necessary upstaging of
patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview,
bladder cancer management decisions can be made more appropriately.
The poster presentation (Abstract No. 686, Poster Session B: Urothelial
Carcinoma) "Upstaging and risk mitigation with Blue Light Cystoscopy for non
-muscle-invasive bladder cancer: Results from a prospective multicenter
registry" by Alireza Ghoreifi (Duke University Medical Center).
The study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with
Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion
detected exclusively by BLC while having a negative WLC. These lesions (335 in
total) included carcinoma in-situ (CIS) (145